Using Thymosin-alpha 1 to prevent cancer recurrence after surgery for high-risk colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy and safety of thymosin-alpha 1 as an adjuvant treatment for patients with high-risk stage II and III colorectal cancer following radical resection. Participants will be randomly assigned to receive thymosin-alpha 1 twice a week for six months or to a control group receiving standard care without the drug. All patients will also undergo chemotherapy or radiotherapy as per established guidelines. The primary goal is to evaluate the three-year disease-free survival rate among the participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Colorectal cancer receiving radical resection
* Pathologically diagnosed with high-risk stage II or stage III
* Eastern Cooperative Oncology Group performance status of 0-2
* Adequate hepatic, renal, and hematologic function

Exclusion Criteria:

* Had previously taken any immune-promoting drugs
* Pregnancy or lactation

Where it's running

• Zhongshan Hospital, Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jianmin Xu, Dr.
• Email: xujmin@aliyun.com
• Phone: +86-021-64041990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Active surveillance after immunotherapy for MMR-deficient colorectal and GI cancers

  This study looks at whether some patients with non-metastatic, MMR-deficient or MSI-H colorectal cancers can skip surgery after a strong response to immunotherapy.

  Recruiting at 3 sites University Hospital, Basel, Switzerland · Basel and 2 other locations · NCT07829081

• Testing stool samples for cancer detection in colorectal cancer survivors

  This study is testing if a new stool test can help find polyps and cancer in colorectal cancer survivors to see if it works better than regular check-ups.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT04624555

• Exploring how exercise affects cancer recurrence

  This study is testing how different levels of aerobic exercise can help reduce the chances of cancer coming back in people who have been treated for breast, prostate, or colorectal cancer.

  Recruiting City of Hope Medical Center · Durate, California and 8 other locations · NCT04589468

• Using fluorescence imaging and light therapy to improve surgery outcomes for advanced colorectal cancer

  This study is testing if using special light to help surgeons see cancer better during surgery, followed by light therapy to kill leftover cancer cells, can improve outcomes for people with advanced colorectal cancer.

  Recruiting Phase 1/2 Roswell Park Cancer Institute · Buffalo, New York · NCT06307548

• Using ctDNA methylation to guide chemotherapy for high-risk colorectal cancer

  This study is testing whether using a blood test to check for cancer DNA can help doctors choose the best chemotherapy for patients with high-risk colorectal cancer after surgery to improve their chances of recovery.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05954078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.